来自自然来源的FAAH调节剂:一系列新的潜在药物
Catalin Nicoara1, Filomena Fezza2, Mauro Maccarrone1,3
1Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio, Coppito, 67100 L'Aquila, Italy.
Cells
|April 11, 2025
概括
天然化合物可以抑制脂肪酸胺基酸酶 (FAAH),这是一个在内分泌系统 (ECS) 中分解安纳米德的酶. 这为各种疾病提供了更安全的治疗方法.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 生物化学 生化学
背景情况:
- 内分泌系统 (ECS) 对于维持平衡,调节免疫反应,新陈代谢和认知功能至关重要.
- 该ECS包括内分泌素,大麻素受体和酶,并与各种病理状况有关.
- 调节ECS,特别是通过抑制脂肪酸胺酸酶 (FAAH),是一种有前途的治疗策略.
研究的目的:
- 探索天然物质作为脂肪酸胺酸酶 (FAAH) 抑制剂的潜力.
- 评估天然化合物作为合成抑制剂的更安全替代品,用于针对内分泌系统 (ECS) 的治疗应用.
主要方法:
- 对自然化合物及其与内分泌系统 (ECS) 的相互作用进行当前研究的综述.
- 专注于植物化合物抑制脂肪酸胺酸酶 (FAAH) 的作用.
- 分析天然FAAH抑制剂的结构多样性和生物活性.
主要成果:
- 自然物质,包括植物性大麻素,黄素和黄素,证明有效抑制FAAH.
- 这些天然化合物与合成抑制剂相比,具有潜在较低的毒性概况.
- 自然抑制剂的结构多样性为药理学发展提供了有价值的替代品.
结论:
- 自然FAAH抑制剂是药理学研究的一个有前途的领域.
- 植物衍生化合物为合成药物提供了更安全和多样化的替代品,用于调节内分泌系统 (ECS).
- 进一步开发天然抑制剂可能会导致创新的治疗工具.
更多相关视频
07:16Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
相关概念视频
01:24Principles of Drug Action
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...